## Hannu Juhani Koponen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5921551/publications.pdf

Version: 2024-02-01

99 papers

2,797 citations

218592 26 h-index 197736 49 g-index

101 all docs

101 docs citations

101 times ranked 3932 citing authors

#	Article	IF	Citations
1	Work incapacity among family caregivers: a record linkage study. Journal of Epidemiology and Community Health, 2022, 76, 580-585.	2.0	1
2	A longitudinal study of restless legs symptoms among patients with depression. Nordic Journal of Psychiatry, 2022, 76, 584-590.	0.7	3
3	Incidence and mortality of alcoholâ€related dementia and Wernickeâ€Korsakoff syndrome: A nationwide register study. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	10
4	Characteristics and predictors of offâ€label use of antipsychotics in general population sample. Acta Psychiatrica Scandinavica, 2022, 146, 227-239.	2.2	4
5	Criminal Behavior in the Four Years Preceding Diagnosis of Neurocognitive Disorder: A Nationwide Register Study in Finland. American Journal of Geriatric Psychiatry, 2021, 29, 657-665.	0.6	10
6	Physical activity and ability to meet different work requirements among adult working men with or without current depressive symptoms. International Archives of Occupational and Environmental Health, 2021, 94, 451-458.	1.1	1
7	Use of antidepressants among Finnish family caregivers: a nationwide register-based study. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 2209-2216.	1.6	4
8	Predictors of response to pharmacological treatments in treatment-resistant schizophrenia – A systematic review and meta-analysis. Schizophrenia Research, 2021, 236, 123-134.	1.1	10
9	Does baseline leisure-time physical activity level predict future depressive symptoms or physical activity among depressive patients? Findings from a Finnish five-year cohort study. Nordic Journal of Psychiatry, 2021, 75, 356-361.	0.7	1
10	The influence of restless legs symptoms on musculoskeletal pain in depression. Scandinavian Journal of Pain, 2020, 20, 603-610.	0.5	O
11	The profiles of health care utilization among a non-depressed population and patients with depressive symptoms with and without clinical depression. Scandinavian Journal of Primary Health Care, 2019, 37, 312-318.	0.6	18
12	Leisure time physical activity and its relation to psychiatric comorbidities in depression. Findings from Finnish Depression and Metabolic Syndrome in Adults (FDMSA) study. Journal of Affective Disorders, 2019, 259, 150-153.	2.0	8
13	Prevalence of restless legs symptoms according to depressive symptoms and depression type: a cross-sectional study. Nordic Journal of Psychiatry, 2018, 72, 51-56.	0.7	15
14	Elevation of tumor necrosis factor alpha levels is associated with restless legs symptoms in clinically depressed patients. Journal of Psychosomatic Research, 2018, 115, 1-5.	1.2	5
15	T78. LONG-TERM PROGNOSIS OF SCHIZOPHRENIA - RESULTS FROM THE NORTHERN FINLAND BIRTH COHORT 1966. Schizophrenia Bulletin, 2018, 44, S144-S145.	2.3	O
16	Does level of leisure time physical activity, in a sample of patients with depression, predict health care utilization over a subsequent 5-year period? Findings from a Finnish cohort study. Mental Health and Physical Activity, 2018, 15, 40-44.	0.9	5
17	Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses $\hat{a} \in \text{``Systematic'}$ reviews and birth cohort study. Psychiatry Research - Neuroimaging, 2018, 281, 43-52.	0.9	3
18	Musculoskeletal Pain in Melancholic and Atypical Depression. Pain Medicine, 2017, 18, pnw202.	0.9	8

#	Article	IF	Citations
19	Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Research, 2017, 247, 130-138.	1.7	68
20	Physical restraints and associations with neuropsychiatric symptoms and personal characteristics in residential care: a crossâ€sectional study. International Journal of Geriatric Psychiatry, 2017, 32, 1418-1424.	1.3	5
21	Long-term antipsychotic and benzodiazepine use and brain volume changes in schizophrenia: The Northern Finland Birth Cohort 1966 study. Psychiatry Research - Neuroimaging, 2017, 266, 73-82.	0.9	21
22	Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 293-302.	0.7	17
23	Antipsychotic drug use and associations with neuropsychiatric symptoms in persons with impaired cognition: a cross-sectional study. Nordic Journal of Psychiatry, 2016, 70, 621-625.	0.7	7
24	Depressive symptoms are associated with poor outcome for lumbar spine surgery. Scandinavian Journal of Pain, 2016, 12, 13-17.	0.5	10
25	Use of psychiatric medications in schizophrenia and other psychoses in a general population sample. Psychiatry Research, 2016, 235, 160-168.	1.7	11
26	Talking about paranoid experiences: Interactional dynamics of accomplishing disclosure of psychotic symptoms in triadic conversation. Communication and Medicine, 2016, 12, 25-40.	0.1	3
27	Cardiometabolic risk factors in patients referred to depression nurse case managers. Nordic Journal of Psychiatry, 2015, 69, 262-267.	0.7	11
28	Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study. BMC Geriatrics, 2015, 15, 100.	1.1	8
29	Association between suicidal behaviour and impaired glucose metabolism in depressive disorders. BMC Psychiatry, 2015, 15, 163.	1.1	68
30	Altered resting-state activity in seasonal affective disorder. Human Brain Mapping, 2014, 35, 161-172.	1.9	30
31	Use of antidepressant medication and suicidal ideationâ€"the Northern Finland Birth Cohort 1966. Human Psychopharmacology, 2014, 29, 559-567.	0.7	3
32	Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia — An observational 9-year follow-up study. Schizophrenia Research, 2014, 158, 134-141.	1.1	66
33	Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication. PLoS ONE, 2014, 9, e101689.	1.1	92
34	Association between vitamin b12 levels and melancholic depressive symptoms: a Finnish population-based study. BMC Psychiatry, 2013, 13, 145.	1.1	32
35	Association between the duration of untreated psychosis and short- and long-term outcome in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophrenia Research, 2013, 143, 3-10.	1.1	25
36	Financial satisfaction and its relationship to depressive symptoms in middle-aged and older adults: Results from the FIN-D2D survey. International Journal of Social Psychiatry, 2013, 59, 239-246.	1.6	17

#	Article	IF	CITATIONS
37	Disordered semantic activation in disorganized discourse in schizophrenia: a new pragmaâ€linguistic tool for structure and meaning reconstruction. International Journal of Language and Communication Disorders, 2013, 48, 320-328.	0.7	4
38	Use of antipsychotic medication and suicidalityâ€"the Northern Finland Birth Cohort 1966. Human Psychopharmacology, 2012, 27, 476-485.	0.7	9
39	Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort. Pharmacoepidemiology and Drug Safety, 2012, 21, 1227-1231.	0.9	28
40	Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study. Journal of Affective Disorders, 2012, 136, 543-549.	2.0	40
41	Association between folate intake and melancholic depressive symptoms. A Finnish population-based study. Journal of Affective Disorders, 2012, 138, 473-478.	2.0	12
42	Lifetime leisure-time physical activity and the risk of depressive symptoms at the ages of 65–74years: The FIN-D2D survey. Preventive Medicine, 2012, 54, 313-315.	1.6	16
43	Psychological Distress Predicts the Development of the Metabolic Syndrome: A Prospective Population-Based Study. Psychosomatic Medicine, 2011, 73, 158-165.	1.3	58
44	Separable developmental trajectories in schizophrenia from womb to grave. Lifespan results from the Northern Finland 1966 Birth Cohort (NFBC 1966). International Clinical Psychopharmacology, 2011, 26, e95-e96.	0.9	0
45	Psychological distress and C-reactive protein: do health behaviours and pathophysiological factors modify the association?. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 277-284.	1.8	20
46	Association of Depressive Symptoms With Impaired Glucose Regulation, Screen-Detected, and Previously Known Type 2 Diabetes. Diabetes Care, 2011, 34, 71-76.	4.3	32
47	Meta-analysis of Paternal Age and Schizophrenia Risk in Male Versus Female Offspring. Schizophrenia Bulletin, 2011, 37, 1039-1047.	2.3	167
48	Advanced Paternal Age, Mortality, and Suicide in the General Population. Journal of Nervous and Mental Disease, 2010, 198, 404-411.	0.5	15
49	Agreement between selfâ€reported and pharmacy data on medication use in the Northern Finland 1966 Birth Cohort. International Journal of Methods in Psychiatric Research, 2010, 19, 88-96.	1.1	42
50	Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis. Schizophrenia Bulletin, 2010, 36, 1115-1130.	2.3	275
51	The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: A Northern Finland 1966 Birth Cohort Study. World Journal of Biological Psychiatry, 2010, 11, 262-267.	1.3	18
52	Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. World Journal of Biological Psychiatry, 2010, 11, 834-839.	1.3	42
53	Association between duration of untreated psychosis and brain morphology in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophrenia Research, 2010, 123, 145-152.	1.1	35
54	Effect of menopause and use of contraceptives/hormone therapy on association of C-reactive protein and depression: A population-based study. Journal of Psychosomatic Research, 2010, 68, 573-579.	1,2	5

#	Article	IF	Citations
55	Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Research, 2010, 178, 121-125.	1.7	21
56	Leisure-time physical activity and metabolic syndrome plus depressive symptoms in the FIN-D2D survey. Preventive Medicine, 2010, 51, 466-470.	1.6	16
57	Gender-specific association of psychological distress with cardiovascular risk scores. Scandinavian Journal of Primary Health Care, 2010, 28, 36-40.	0.6	12
58	Management of depression in the presence of pain symptoms. Psychiatria Danubina, 2010, 22, 4-13.	0.2	14
59	Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial. World Journal of Biological Psychiatry, 2009, 10, 710-718.	1.3	14
60	Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Research, 2009, 167, 73-79.	1.7	47
61	Suicides Among Older Persons in Finland and Time Since Hospitalization Discharge. Psychiatric Services, 2009, 60, 390-393.	1.1	12
62	Schizophrenia and sudden cardiac death—A review. Nordic Journal of Psychiatry, 2008, 62, 342-345.	0.7	99
63	Metabolic Syndrome Predisposes to Depressive Symptoms. Journal of Clinical Psychiatry, 2008, 69, 178-182.	1.1	145
64	Socio-demographic and clinical predictors of occupational status in schizophrenic psychoses—follow-up within the Northern Finland 1966 Birth Cohort. Psychiatry Research, 2007, 150, 217-225.	1.7	24
65	A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety, 2007, 24, 1-14.	2.0	88
66	Rates and previous disease history in old age suicide. International Journal of Geriatric Psychiatry, 2007, 22, 38-46.	1.3	36
67	Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 100-107.	0.6	87
68	Patterns of psychiatric hospitalizations in schizophrenic psychoses within the Northern Finland 1966 Birth Cohort. Nordic Journal of Psychiatry, 2006, 60, 286-293.	0.7	13
69	Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966 Birth Cohort Study. Schizophrenia Research, 2006, 84, 15-19.	1.1	25
70	Statistical methodologies in psychopharmacology: a review. Human Psychopharmacology, 2006, 21, 195-203.	0.7	8
71	Risk factors for schizophrenia. Follow-up data from the Northern Finland 1966 Birth Cohort Study. World Psychiatry, 2006, 5, 168-71.	4.8	16
72	Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study. European Neuropsychopharmacology, 2005, 15, 617-623.	0.3	16

#	Article	IF	Citations
73	Sedative Drug Use in the Home-Dwelling Elderly. Annals of Pharmacotherapy, 2004, 38, 2017-2022.	0.9	41
74	Childhood central nervous system infections and risk for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 9-13.	1.8	95
<b>7</b> 5	Developmental precursors of psychosis. Current Psychiatry Reports, 2004, 6, 168-175.	2.1	17
76	Reversal of antipsychotic-induced weight gain during quetiapine treatment. International Clinical Psychopharmacology, 2003, 18, 355-356.	0.9	2
77	Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 294-298.	1.8	23
78	Neurochemistry and Delirium. Dementia and Geriatric Cognitive Disorders, 1999, 10, 339-341.	0.7	18
79	A Controlled, Prospective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder. Journal of Clinical Psychiatry, 1998, 59, 528-534.	1.1	95
80	Risperidone in the Treatment of Psychosis and Concomitant Buccolinguomasticatory Dyskinesia in the Elderly., 1997, 12, 412-413.		3
81	Adolescent conduct disorder, depression, and central nervous system demyelinization in magnetic resonance imaging:A report with two cases. Nordic Journal of Psychiatry, 1996, 50, 419-421.	0.7	1
82	Paroxetine increases serum trimipramine concentration. A report of two cases. Human Psychopharmacology, 1995, 10, 345-347.	0.7	17
83	A long-term follow-up study of cerebrospinal fluid 5-hydroxyindoleacetic acid in delirium. European Archives of Psychiatry and Clinical Neuroscience, 1994, 244, 131-134.	1.8	14
84	A long-term follow-up study of cerebrospinal fluid acetylcholinesterase in delirium. European Archives of Psychiatry and Clinical Neuroscience, 1994, 243, 347-351.	1.8	10
85	Serum mianserin and ageing. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 833-845.	2.5	166
86	Normal neuropathological findings after neuroleptic malignant syndrome. Human Psychopharmacology, 1993, 8, 217-219.	0.7	0
87	Neuroleptic malignant syndrome during remoxipride treatment. A case report. European Neuropsychopharmacology, 1993, 3, 517-519.	0.3	4
88	A prospective study of delirium in elderly patients admitted to a psychiatric hospital. Psychological Medicine, 1993, 23, 103-109.	2.7	51
89	Delirium During Fluoxetine Treatment: A Case Report. Annals of Clinical Psychiatry, 1993, 5, 255-257.	0.6	10
90	Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment. Psychiatry Research, 1992, 44, 107-112.	1.7	30

#	Article	IF	CITATIONS
91	A longitudinal study of cerebrospinal fluid acetylcholinesterase in delirium: Changes at the acute stage and at one-year followup. Psychiatry Research, 1991, 38, 135-142.	1.7	5
92	Delirium in the Elderly: A Brief Overview. International Psychogeriatrics, 1991, 3, 177-179.	0.6	1
93	Electroencephalographic Indices for Diagnosis of Delirium. International Psychogeriatrics, 1991, 3, 249-251.	0.6	4
94	Cerebrospinal fluid somatostatin in delirium. II Changes at the acute stage and at one year follow-up. Psychological Medicine, 1990, 20, 501-505.	2.7	12
95	Epileptic Attack, Delirium, and a Creutzfeldt-Jakob-Like Syndrome during Mianserin Treatment. Neuropsychobiology, 1990, 23, 164-168.	0.9	11
96	Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment. Psychiatry Research, 1990, 33, 307-312.	1.7	25
97	CSF beta-endorphin-like immunoreactivity in delirium. Biological Psychiatry, 1989, 25, 938-944.	0.7	15
98	Cerebrospinal fluid somatostatin in delirium. Psychological Medicine, 1989, 19, 605-609.	2.7	16
99	Benefits and risks of off label use of antipsychotics in insomnia and anxiety $\hat{a} \in \text{APSY Oulu project.}$ Nordic Journal of Psychiatry, 0, , 1-1.	0.7	O